dichlororibofuranosylbenzimidazole has been researched along with Liver Neoplasms in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hod, Y | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Liver Neoplasms
| Article | Year |
|---|---|
The degradation of phosphoenopyruvate carboxykinase (GTP) mRNA is regulated by cyclic AMP but not by dexamethasone.
Topics: Animals; Cell Line; Cell Nucleus; Cyclic AMP; Dexamethasone; Dichlororibofuranosylbenzimidazole; Gen | 1994 |